Clinical Trial Update: Anti-MART-1 F5 Lymphocytes to Treat High-Risk Melanoma Patients [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating anti-MART-1 F5 lymphocytes for high-risk melanoma has been terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-MART-1 F5 Lymphocytes

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2013-03-19